| Dr Subhadra Mandadi, MD | |
|
3100 Maccorkle Ave Se Ste 902, Charleston, WV 25304-1234 | |
| (304) 388-6590 | |
| (304) 388-6595 |
| Full Name | Dr Subhadra Mandadi |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 17 Years |
| Location | 3100 Maccorkle Ave Se Ste 902, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396021929 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 27497 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Bellevue Medical Center | Bellevue, NE | Hospital |
| Mary Lanning Healthcare | Hastings, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Madonna Rehabilitation Hospital | 0446164081 | 56 |
| The Mary Lanning Memorial Hospital Association | 4587575550 | 117 |
| Unmc Physicians | 6002728391 | 1320 |
News Archive
MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
Boston University's Technology Development Office, on behalf of Boston Medical Center, Northeastern University, and Massachusetts Institute of Technology (MIT), has completed the exclusive license of Project RED (Re-Engineered Discharge) to Engineered Care, Inc.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
› Verified 1 days ago
| Entity Name | Unmc Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417912114 PECOS PAC ID: 6002728391 Enrollment ID: O20031104000664 |
News Archive
MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
Boston University's Technology Development Office, on behalf of Boston Medical Center, Northeastern University, and Massachusetts Institute of Technology (MIT), has completed the exclusive license of Project RED (Re-Engineered Discharge) to Engineered Care, Inc.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
› Verified 1 days ago
| Entity Name | Madonna Rehabilitation Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417045642 PECOS PAC ID: 0446164081 Enrollment ID: O20031118000079 |
News Archive
MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
Boston University's Technology Development Office, on behalf of Boston Medical Center, Northeastern University, and Massachusetts Institute of Technology (MIT), has completed the exclusive license of Project RED (Re-Engineered Discharge) to Engineered Care, Inc.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
› Verified 1 days ago
| Entity Name | The Mary Lanning Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356656417 PECOS PAC ID: 4587575550 Enrollment ID: O20101007000817 |
News Archive
MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
Boston University's Technology Development Office, on behalf of Boston Medical Center, Northeastern University, and Massachusetts Institute of Technology (MIT), has completed the exclusive license of Project RED (Re-Engineered Discharge) to Engineered Care, Inc.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Subhadra Mandadi, MD 3100 Maccorkle Ave Se Ste 902, Charleston, WV 25304-1234 Ph: (304) 388-6590 | Dr Subhadra Mandadi, MD 3100 Maccorkle Ave Se Ste 902, Charleston, WV 25304-1234 Ph: (304) 388-6590 |
News Archive
MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
Boston University's Technology Development Office, on behalf of Boston Medical Center, Northeastern University, and Massachusetts Institute of Technology (MIT), has completed the exclusive license of Project RED (Re-Engineered Discharge) to Engineered Care, Inc.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
› Verified 1 days ago
Dr. Asif Rahman, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2345 Chesterfield Ave, Suite 301, Charleston, WV 25304 Phone: 304-344-2900 Fax: 304-344-9385 | |
David L Namay, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 3411 B Noyes Avenue Se, Charleston, WV 25304 Phone: 304-720-3206 Fax: 304-720-3207 | |
Joseph Jarrell, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 333 Laidley St Ste 605, Charleston, WV 25301 Phone: 304-720-7235 Fax: 304-720-7236 | |
Samar Ryiad Sankari, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1097 Fledderjohn Rd, Charleston, WV 25314 Phone: 304-720-1963 Fax: 304-720-1966 | |
Brittain Mcjunkin, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3110 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-347-1300 | |
Rupali N. Sangrampurkar, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-5848 Fax: 304-388-9654 | |
George Zaldivar, M.D Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3100 Maccorkle Avenue Se, Suite 404, Charleston, WV 25304 Phone: 304-346-1811 Fax: 304-343-3086 |